

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ Application No. 10/699,068, filed on October 30, 2003
- ☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

Full Name of Inventor(s)Inventor 1 Qiyue HUSignature Citizen of People's Republic
Of ChinaInventor 2 Ted William JOHNSONSignature Citizen of USAInventor 3 Atsuo KUKISignature Citizen of USAInventor 4 Michael Bruno PLEWESignature Citizen of Germany☒ Additional inventors are being named on page 2

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Page 2

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ Application No. 10/699,068, filed on October 30, 2003
- ☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;


I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

Inventor 5 **Dawn Marie NOWLIN**


Signature



Citizen of USA

Inventor 6 **Hai WANG**


Signature



Citizen of People's Republic
Of China

Inventor 7 **Junhu ZHANG**

Signature



Citizen of Canada


ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged, We, **Qiyue HU** of 7801 Centella Street, Unit #1, Carlsbad, CA 92009; **Atsuo KUKI** of 1261 Rancho Encinitas Drive, Encinitas, California 92024; **Dawn Marie NOWLIN** of 11858 Wilmington Road, San Diego, California 92128; **Michael Bruno PLEWE** of 4711 Caminito Avenue, San Diego, California 92130; **Hai WANG** of 11087 Ice Skate Place, San Diego, California 92126; and **Junhu ZHANG** of 3445 Lebon Drive, Apt. #1423, San Diego, CA 92122, respectively, **Ted William JOHNSON** of 101 W. Paseo de Cristobal, San Clemente, CA 92672, United States of America; hereby sell, assign and transfer unto AGOURON PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of California, United States of America, and having a place of business at 10777 Science Center Drive, San Diego, California 92121, United States of America, our entire right, title and interest, except as limited herein below, in and to provisional patent application of the United States of America, having PFIZER INC. Docket No.: PC25050A, entitled **HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE**; filed in the United States Patent and Trademark Office on **October 30, 2003** and assigned application number **10/699,068**; and our entire right, title and interest, in the United States of America, in and to all our inventions, whether joint or sole, disclosed in said patent application; and our entire right, title and interest in and to all applications filed in the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted in the United States of America on the foregoing applications;


and we hereby sell, assign and transfer unto PFIZER INC., a corporation organized and existing under the laws of the State of Delaware, United States of America, and having a place of business at 235 East 42nd Street, New York, New York 10017, United States of America, our entire right, title and interest, in all countries of the world except the United States of America, in and to all our inventions, whether joint or sole, disclosed in said provisional patent application; and our entire right, title and interest in and to all patent applications filed outside the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted outside the United States of America on said patent applications filed outside the United States of America; and the right to claim priority from said provisional patent application under the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements to which the United States of America is a party and which afford similar priority-claiming privileges, in all countries of the world except the United States of America;

and we hereby agree, whenever requested, to communicate to said AGOURON PHARMACEUTICALS, INC. and said PFIZER INC., and their successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding respecting said inventions,

and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in all countries of the world.

Signed and witnessed this 5th day of October 2004 at
San Diego, CA

Ted William JOHNSON

In the presence of:


Pamela Hollander

ASSIGNMENT


For valuable consideration, the receipt and adequacy of which is hereby acknowledged, we, Qiyue HU of 11028 Via Asti, San Diego, California, 92129, USA; Atsuo KUKI of 1261 Rancho Encinitas Drive, Encinitas, California 92024, USA; Dawn Marie NOWLIN of 11858 Wilmington Road, San Diego, California 92128, USA; Michael Bruno PLEWE of 4711 Caminito Eva, San Diego, California 92130, USA; Hai WANG of 11087 Ice Skate Place, San Diego, California 92126, USA; and Junhu Zhang of 3445 Lebon Drive, Apartment #1423, San Diego, California 92122, USA, respectively, hereby sell, assign and transfer unto AGOURON PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of California, United States of America, and having a place of business at 10777 Science Center Drive, San Diego, California 92121, United States of America, our entire right, title and interest, except as limited herein below, in and to provisional patent application of the United States of America, having PFIZER INC. Docket No.: PC025050, entitled **HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE**; filed in the United States Patent and Trademark Office on **October 31, 2002** and assigned application number **60/422,513**; and our entire right, title and interest, in the United States of America, in and to all our inventions, whether joint or sole, disclosed in said patent application; and our entire right, title and interest in and to all applications filed in the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted in the United States of America on the foregoing applications;

and we hereby sell, assign and transfer unto PFIZER INC., a corporation organized and existing under the laws of the State of Delaware, United States of America, and having a place of business at 235 East 42nd Street, New York, New York 10017, United States of America, our entire right, title and interest, in all countries of the world except the United States of America, in and to all our inventions, whether joint or sole, disclosed in said provisional patent application; and our entire right, title and interest in and to all patent applications filed outside the United States of America for Letters Patent for any or all of said inventions; and our

entire right, title and interest in and to all Letters Patent granted outside the United States of America on said patent applications filed outside the United States of America; and the right to claim priority from said provisional patent application under the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements to which the United States of America is a party and which afford similar priority-claiming privileges, in all countries of the world except the United States of America;

and we hereby agree, whenever requested, to communicate to said AGOURON PHARMACEUTICALS, INC. and said PFIZER INC., and their successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding respecting said inventions, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in all countries of the world.


Signed and witnessed this 24th day of June 2003 at
San Diego, CA USA



Qiyue Hu


In the presence of:






[print name here, sign above]

Signed and witnessed this 24th day of June 2003 at
San Diego CA USA


Atsuo Kuki

In the presence of:




Danielle Dixon
[print name here, sign above]

Signed and witnessed this 19th day of June 2003 at
San Diego CA USA


Dawn Marie Nowlin

In the presence of:



Danielle Dixon
[print name here, sign above]

Signed and witnessed this 24 day of June 2003 at
San Diego CA 92121

Michael Bruno Plewe
Michael Bruno Plewe

In the presence of:

Danielle Dixon

Danielle Dixon

[print name here, sign above]

Signed and witnessed this 19th day of June, 2003 at
San Diego, CA, USA


Hai Wang


In the presence of:

Danielle Dixon

Danielle Dixon

[print name here, sign above]

Signed and witnessed this 19th day of June 2003 at
San Diego, CA 92121


Junhu Zhang

In the presence of:



Danielle Dixon

[print name here, sign above]